GemPharmatech Co

GemPharmatech Co Total Assets

The Total Assets of GemPharmatech Co (688046.SS) as of Oct 22, 2026 is 2.87 B CNY. In the previous year, Total Assets was 2.57 B CNY — a change of 11.37% (higher).

Total Assets

2.87 BCNY

YoY

11.37%

Last updated:

Total Assets of GemPharmatech Co is 2025 2.87 B CNY. Total Assets of GemPharmatech Co was 2024 2.57 B CNY. It decreases by 11.37% higher compared to the previous year.

The GemPharmatech Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
104.71 M CNY
Jan 1, 2019
388.14 M CNY
Jan 1, 2020
883.19 M CNY
Jan 1, 2021
1.05 B CNY
Jan 1, 2022
2.25 B CNY
Jan 1, 2023
2.58 B CNY
Jan 1, 2024
2.57 B CNY
Jan 1, 2025
2.87 B CNY
The GemPharmatech Co Total Assets history
YEARTotal AssetsYoY
2.87 BCNY+11.37%
2.57 BCNY-0.19%
2.58 BCNY+14.37%
2.25 BCNY+113.74%
1.05 BCNY+19.39%
883.19 MCNY+127.55%
388.14 MCNY+270.67%
104.71 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Total Assets of GemPharmatech Co is 2.87 B CNY in 2025.

Total Assets of GemPharmatech Co changed from 2.57 B CNY to 2.87 B CNY, representing a 11.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GemPharmatech Co

All Key Metrics — GemPharmatech Co